Klippstein T, Graubner M, Berdel W E, Mende S, Gropp C, Diehl V, Mitrou P S
Onkologie. 1983 Dec;6(6):306-11. doi: 10.1159/000215253.
Forty-six patients with non-small cell lung cancer were treated with a combination of cis-platinum 90 mg/m2 i.v., day 1 and VP 16-213 100 mg/m2 i.v. on days 1, 3 and 5. The overall remission rate was 22% (10 out of 46 patients) with a median remission duration of 7 months. Squamous cell and large cell undifferentiated carcinomas responded to the chemotherapy with a remission rate of 27% (7 out of 26 patients) and 22% (3 out of 13 patients). Seven patients with adeno-carcinoma did not respond to chemotherapy. The overall survival was 7 months (1-27+). The survival time for patients entering remission was 11.5 months (7-27+), for those with stable disease 8.5 months (3-27+), and for patients with progressive disease 5 months (1-9). Performance status of less than 80%, a weight loss of more than 10.0 kg in the last three months before starting treatment and a "major" atelectasis (collapse of at least one superior or inferior lobe) adversely influenced prognosis. Only 1 out of 31 patients with one or more poor prognostic factors came into remission. In contrast, 9 out of 15 patients (60%) without poor prognostic factors had a remission. Stage, limited versus extensive disease, and age did not affect the results. Hematologic and renal toxicity of the combination were mild, but poor subjective tolerance (nausea, vomiting, loss of appetite) was prominent.
46例非小细胞肺癌患者接受了如下联合治疗：第1天静脉注射顺铂90mg/m²，第1、3和5天静脉注射依托泊苷100mg/m²。总缓解率为22%（46例患者中有10例），中位缓解持续时间为7个月。鳞状细胞癌和大细胞未分化癌对化疗有反应，缓解率分别为27%（26例患者中有7例）和22%（13例患者中有3例）。7例腺癌患者对化疗无反应。总生存期为7个月（1 - 27 +）。进入缓解期的患者生存时间为11.5个月（7 - 27 +），病情稳定的患者为8.5个月（3 - 27 +），病情进展的患者为5个月（1 - 9）。体能状态低于80%、开始治疗前三个月体重减轻超过10.0kg以及“大片”肺不张（至少一个上叶或下叶萎陷）对预后有不利影响。31例有一个或多个不良预后因素的患者中只有1例进入缓解期。相比之下，15例无不良预后因素的患者中有9例（60%）出现缓解。分期（局限期与广泛期）和年龄不影响治疗结果。该联合治疗的血液学和肾脏毒性较轻，但主观耐受性差（恶心、呕吐、食欲不振）较为突出。
